CYP3A诱导可预测P-糖蛋白诱导:递增剂量利福平建立诱导关系
本研究在健康受试者中使用递增剂量利福平(2、10、75、600 mg q.d.)建立CYP3A与P-gp、OATP、BCRP及CYP2C9、CYP1A2的相对诱导关系。结果显示P-gp、OATP和CYP2C9仅出现中度诱导,且其剂量依赖性诱导程度始终比CYP3A低一个药物相互作用类别。数据证明可利用P450诱导数据推断对转运体的影响。
要点
- 利福平递增剂量可产生弱、中、强PXR激动效应。
- P-gp、OATP和CYP2C9的诱导程度均低于CYP3A。
- P450诱导数据可外推预测转运体诱导效应。
核心结论
- P-gp、OATP和CYP2C9的剂量依赖性诱导始终比CYP3A低一个药物相互作用类别。
- P450诱导数据可为转运体诱导效应提供概念验证。
研究设计与样本
- 健康受试者接受达比加群酯、普伐他汀、瑞舒伐他汀及咪达唑仑/甲苯磺丁脲/咖啡因鸡尾酒,在利福平2、10、75或600 mg q.d.前后给药。
- 使用递增剂量利福平激发弱、中、强PXR激动效应。
主要发现
- 与CYP3A不同,P-gp、OATP和CYP2C9仅观察到中度诱导。
- P-gp、OATP和CYP2C9的剂量依赖性诱导始终比CYP3A低一个药物相互作用类别,即使校正探针药物敏感性后仍如此。
临床怎么用
- 临床可利用CYP3A诱导数据推断对P-gp、OATP等转运体的诱导程度及药物相互作用风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Drug transporter and cytochrome P450 expression is regulated by shared nuclear receptors and, hence, an inducer should induce both, although the magnitude may differ. The objective of this study was to establish relative induction relationships between CYP3A and drug transporters (P-glycoprotein (P-gp), organic anion transporting polypeptide (OATP), and breast cancer resistance protein (BCRP)) or other P450s (CYP2C9 and CYP1A2) using ascending doses of the prototypical pregnane xenobiotic receptor (PXR) agonist, rifampin, to elicit weak, moderate, and strong PXR agonism. Healthy subjects received dabigatran etexilate, pravastatin, rosuvastatin, and a midazolam/tolbutamide/caffeine cocktail before and after rifampin 2, 10, 75, or 600 mg q.d. Unlike CYP3A, only moderate induction of P-gp, OATP, and CYP2C9 was observed and dose-dependent induction of P-gp, OATP, and CYP2C9 was always one drug-drug interaction category lower than observed for CYP3A, even when correcting for probe drug sensitivity. Data from this study establish proof-of-concept that P450 induction data can be leveraged to inform on the effect on transporters.
引用
- Lutz JD, Kirby BJ, Wang L, et al. Cytochrome P450 3A Induction Predicts P-glycoprotein Induction; Part 1: Establishing Induction Relationships Using Ascending Dose Rifampin. Clin Pharmacol Ther. 2018. PMID: 29569723. doi:10.1002/cpt.1073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。